Norges Bank’s Anika Therapeutics ANIK Stock Holding History

Norges Bank’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,100	Closed	-$1.04M	–	2017
2023 Q1	$1.04M	Buy	+36,100	New	+$1.07M	﹤0.01%	2000
2022 Q4	–	Sell	-56,700	Closed	-$1.35M	–	2134
2022 Q3	$1.35M	Hold	56,700	–	–	﹤0.01%	1971
2022 Q2	$1.27M	Hold	56,700	–	–	﹤0.01%	1943
2022 Q1	$1.42M	Hold	56,700	–	–	﹤0.01%	2018
2021 Q4	$2.03M	Buy	+56,700	New	+$2.27M	﹤0.01%	2036
2015 Q3	–	Sell	-500	Closed	-$17K	–	2285
2015 Q2	$17K	Hold	500	–	–	﹤0.01%	2261
2015 Q1	$21K	Hold	500	–	–	﹤0.01%	2271
2014 Q4	$20K	Buy	+500	New	+$19.5K	﹤0.01%	2339

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank's ANIK Position: Q2 2023 in Review

Norges Bank sold out of Anika Therapeutics (ANIK) in Q2 2023, closing a stake of 36,100 shares — an estimated $1.04M sold.

Norges Bank first reported a position in ANIK in Q4 2014 and held it in 8 quarters. The position peaked at $2.03M in Q4 2021. 117 funds tracked by Wall St. Rank hold ANIK as of Q2 2023.

Norges Bank reported no remaining Anika Therapeutics position as of Q2 2023 after selling out during the quarter.
Norges Bank sold 36,100 Anika Therapeutics shares in Q2 2023, an estimated $1.04M.
Norges Bank first reported a position in Anika Therapeutics in Q4 2014 and held it in 8 quarters.
Norges Bank's Anika Therapeutics position peaked at $2.03M in Q4 2021.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.